Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

How anal cancer develops step by step, and what speeds it up

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Anal cancer is not an event. It is the end of a sequence that typically runs over years, through stages that can be seen under a microscope and, at one of those stages, removed.

Understanding the sequence is how you understand why screening and vaccination exist at all.

Related pages: Anal cancer

The bottom line

What we know
  • Low-grade lesions, LSIL or AIN 1, often regress on their own.
  • High-grade lesions, HSIL or AIN 2 and 3, are true precancer.
  • Treating high-grade lesions reduces progression to cancer.
  • HIV, other immunosuppression and smoking accelerate every step.
What is still open
  • Which high-grade lesions will progress and which will regress, in an individual.
  • How much benefit treating high-grade lesions gives in people without HIV, where the trial evidence is thinner.

The story, step by step

  1. 1. Low grade ()
  2. 2. High grade ()
  3. 3. The ANCHOR result ()
  4. 4. Invasion ()
  5. 5. The cofactors ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Usually a passing thing

Review of many studies

What happens

The first visible change is low-grade squamous intraepithelial lesion, also called AIN 1.

What the research shows

  • Viral DNA is usually still episomal, a free circle, rather than integrated into the chromosome.
  • Abnormal cells are confined to the lower third of the epithelium, with mild nuclear changes.
  • This mostly reflects active viral replication rather than a cancerous process.
  • A large proportion regress on their own as the immune system clears the infection.
  • Low-grade lesions are generally not treated, and are followed instead.

Why it matters

Being told you have a low-grade lesion is not being told you are on the way to cancer. Most of these resolve.

What's still uncertain

  • Rates of regression vary between populations and are lower in people with immunosuppression.

Read more

Next: High grade

Part 2 of 5

The stage that matters

Review of many studies

What happens

High-grade squamous intraepithelial lesion, HSIL, covering AIN 2 and AIN 3, is genuine precancer.

What the research shows

  • Viral DNA is more often integrated, and E6 and E7 are produced at high levels.
  • Abnormal, disorganized cells extend through two-thirds or the full thickness of the epithelium.
  • The cells remain above the basement membrane, so this is not yet cancer and has not spread anywhere.
  • HSIL can still regress, particularly in people with intact immunity, but it is much less likely to than low-grade disease.
  • This is the stage screening is designed to find, because removing it prevents the next step.

Why it matters

The whole logic of anal screening rests on this stage existing for years and being removable.

What's still uncertain

  • Pathologists do not always agree on the boundary between AIN 2 and AIN 1, which is why terminology moved toward LSIL and HSIL.

Read more

Next: The ANCHOR result

Part 3 of 5

Treating precancer works

Review of many studies

What happens

Until recently, whether treating anal HSIL actually prevented cancer was an open question. A large trial answered it.

What the research shows

  • The ANCHOR trial enrolled people living with HIV who had anal HSIL and randomly assigned them to treatment of the lesions or to active monitoring.
  • Treatment reduced progression to anal cancer by around 57 percent compared with monitoring.
  • The trial was stopped early in 2021 because the benefit was clear enough that continuing to monitor without treating was no longer justifiable.
  • The result published in 2022 and changed practice: it is the basis for current screening and treatment recommendations in high-risk groups.
  • Treatment of HSIL is usually ablation or excision, often guided by high-resolution anoscopy.

Why it matters

This is one of the clearest recent examples of a trial directly changing what people are offered.

What's still uncertain

  • The trial was conducted in people with HIV, so how far the result extends to other groups is inferred rather than demonstrated.

Read more

Next: Invasion

Part 4 of 5

Breaking through

Review of many studies

What happens

Cancer begins at the moment abnormal cells breach the basement membrane.

What the research shows

  • Below that membrane are blood vessels and lymphatics, which is how spread becomes possible.
  • The tumour can invade the sphincter muscles, and can spread to lymph nodes in the groin and pelvis.
  • Symptoms at this point are bleeding, pain or pressure, a lump, discharge, itching, or a change in the shape of stools.
  • Those symptoms are routinely attributed to haemorrhoids, which is the main cause of delayed diagnosis.
  • Staging uses examination, biopsy, and imaging with CT, MRI or PET as indicated.

Why it matters

The jump from precancer to cancer is a single membrane. Everything preventive happens on one side of it.

What's still uncertain

  • Time from HSIL to invasion varies widely and cannot be predicted individually.

Read more

Next: The cofactors

Part 5 of 5

What shortens the timeline

Review of many studies

What happens

The same sequence runs faster in some people, and the reasons are mostly about immunity.

What the research shows

  • HIV, particularly with a low CD4 count, markedly reduces the ability to clear HPV and raises risk substantially. Men who have sex with men who are living with HIV have the highest documented rates.
  • Immunosuppressive drugs after an organ transplant have a similar effect.
  • Smoking impairs local mucosal immunity and delivers carcinogens that damage basal cell DNA directly. It is the main modifiable cofactor.
  • A history of cervical, vulvar or vaginal HSIL or cancer indicates persistent high-risk HPV and raises anal cancer risk.
  • Receptive anal sex increases the chance of acquiring anal HPV, though anal HPV infection also occurs without it.

Why it matters

Stopping smoking is the one item on this list a person can act on directly, and it matters at every stage.

What's still uncertain

  • How much each cofactor contributes independently is difficult to separate because they frequently overlap.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.